Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
Maravai postpones earnings release, delays annual report
Maravai LifeSciences (MRVI) shares drop 15% premarket as it postpones 2024 earnings release, citing year-end financial review.
Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...